Disease

Paresthesia

Late-stage therapeutic developmentEmerging researchRising momentum

MeSHParesthesia

Publications

Clinical trials

Related conditions

2019

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Research2019-08-16The Lancet. Oncology

Comparison of 10-kHz High-Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial.

Research2016-11-01Neurosurgery

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Research2014-03-03Blood

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

6 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

Effectiveness and Cost-effectiveness of Ozone Treatment in Patients With Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy. Randomized, Triple-blind Clinical Trial (OzoParQT)

Phase 2/3 · Recruiting · Bernardino Clavo, MD, PhD

Evaluation of the Gut Microbiome Profiles in Patients with Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial with Ozone OzoParQT (NCT06706544).

Phase 2/3 · Recruiting · Bernardino Clavo, MD, PhD

Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness

Phase 4 · Recruiting · Hardeep Singh

A Multicentre, Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Acetyllevocarnitine Hydrochloride Tablets in Chinese Patients With Paresthesias Caused by Diabetic Peripheral Neuropathy

Phase 3 · Completed · Haisco Pharmaceutical Group Co., Ltd.

Phase 4 Study of Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy

Phase 4 · Completed · Usak State Hospital

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

Phase 3 · Completed · National Center for Research Resources (NCRR)

Recruiting

Phase 2/3 · Recruiting · Bernardino Clavo, MD, PhD

Evaluation of the Gut Microbiome Profiles in Patients with Chemotherapy-induced Peripheral Neuropathy Treated in the Randomized Clinical Trial with Ozone OzoParQT (NCT06706544).

Phase 2/3 · Recruiting · Bernardino Clavo, MD, PhD

Effect of Depo-Medrol Application on the Psoas Muscle After Transpsoas LLIF on Post-operative Hip Flexor Weakness, Thigh Pain and Numbness

Phase 4 · Recruiting · Hardeep Singh

Recently completed

Phase 3 · Completed · Haisco Pharmaceutical Group Co., Ltd.

Phase 4 Study of Efficacy of Gabapentin in the Treatment of Chest Pain and Paresthesia in Patients With Sternotomy

Phase 4 · Completed · Usak State Hospital

Immunomodulatory and Clinical Effects of Doxycycline on Persistent Symptoms After Treatment of Neuroborreliosis: A Double-blind, Randomised, Crossover Study

N/A · Completed · Linkoeping University

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Mexiletine for Painful Diabetic Neuropathy

Phase 3 · Completed · National Center for Research Resources (NCRR)

Research activity

3 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time

20142019

Most influential

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology · 2019 · 595 cites

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Blood · 2014 · 486 cites

Neurosurgery · 2016 · 340 cites

Recent publications

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology · 2019 · 595 cites

Neurosurgery · 2016 · 340 cites

Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

Blood · 2014 · 486 cites

Leading journals3

Blood1
Neurosurgery1
The Lancet. Oncology1

Leading researchers8

Amin A1
Amirdelfan K1
Arén Frontera O1
Barthélémy P1
Benyamin R1
Beuselinck B1
Bracarda S1
Bundschu R1

Affiliations (unnormalised)6

*Center for Clinical Research and Carolina's Pain Institute1
Aarhus University Hospital1
Barts Cancer Institute1
Beth Israel Deaconess Medical Center1
Cleveland Clinic Taussig Cancer Institute1
Dana-Farber Cancer Institute1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Fatigue2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Subjective cutaneous sensations (e.g., cold, warmth, tingling, pressure, etc.) that are experienced spontaneously in the absence of stimulation.

Identifiers

MeSHParesthesia

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.